Emerging Topics

The published article, Science gave us excellent vaccines. Why bend the rules? in The Globe and Mail addresses the challenges in altering the recommended two-dose schedule for the two Canadian approved mRNA vaccines, Pfizer-BioNTech and Moderna. In this episode of Emerging Topics, we speak to one of the authors, Dr. Alan Bernstein to tell us more about these challenges and what considerations should be taken on whether or not to delay the second-dose. Dr. Alan Bernstein is the President and CEO of the Canadian Institute for Advanced Research (CIFAR), which is a Canadian-based, global research organization. He is one of Canada's foremost scientists with several decades of work in research leadership. A graduate from the University of Toronto, he received the James Loudon Gold Medal in Physics, and completed his PhD research with James Till. After roles at the Ontario Cancer Institute and Lunenfeld Tanenbaum Research Institute, Dr. Bernstein was asked to become the founding President of the Canadian Institutes